Navigation Links
Tengion Provides Business Update and Reports Second Quarter 2013 Financial Results
Date:8/14/2013

, could place the Company's clinical trials on clinical hold; (ii) patients enrolled in the Neo-Urinary Conduit or Neo-Kidney Augment clinical trials may experience adverse events; (iii) the Company may have difficulty enrolling patients in its clinical trials; (iv) data from the Company's ongoing preclinical studies, including the GLP program for the Neo-Kidney Augment, may not continue to be supportive of advancing such preclinical product candidates; and (v) the Company may be unable to progress its product candidates that are undergoing preclinical testing into clinical trials and the Company may not be successful in designing such clinical trials in a manner that supports development of such product candidates. Any of these factors could delay one of the Company's clinical trials or cause the Company to terminate the development of one of its product candidates. For additional factors that could cause actual results to differ from expectations, you should refer to the reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release are made only as of the date hereof and the Company disclaims any intention or responsibility for updating predictions or expectations in this release.TENGION, INC.
(A Development-Stage Company)
Statements of Operations (in thousands, except per share data)(unaudited)Three Months EndedJune 30,Six Months EndedJune 30,2012201320122013Revenue$

—$

—$

—$

—Operating expenses:Research and development$

2,789$

2,480$

5,483$

4,660General and administrative1,4381,4452,8193,295Depreciation11562251145Other expense, net449192121 Total operating expenses4,3864,0788,6458,221 

Loss from operations(4,386)(4,078)(8,645)(8,221) 

Interest income42117Interest expense(151)(1,830)(325)(3,257)Change in fair value of embed
'/>"/>

SOURCE Tengion, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Tengion Reports Second Quarter 2012 Financial Results
2. Tengion to Present at the BIO CEO & Investor Conference
3. Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in Sweden
4. MediPendant™ to Return to Television on May 20th New Television Campaign - Company Provides MediPendant™ Update
5. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
6. Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
7. Simcere Pharmaceutical Group Provides Notice of Annual General Meeting
8. Elevate Provides Remote Access to Personal Health Records Using MyMedicalRecords.com
9. Health Diagnostic Laboratory, Inc. Provides Grant to Support National Lipid Association, Sponsors 2012 Annual Scientific Sessions in Scottsdale, Arizona
10. NexGen Biomedical, Inc. Provides New Insights Into Jett Travoltas Seizure Related Death
11. Concord Medical Announces its Successful Closing of the Acquisition of 52% Ownership in Changan Hospital and Provides Guidance for Financial Results of the Second Quarter of 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Astellas has appointed James Kellerman ... the Americas. Kellerman will report directly to Linda ... Astellas. In his new role, Kellerman will lead a ... and manage the region,s intellectual property matters, coordinating closely ... very pleased to welcome Jim to Astellas. Jim brings ...
(Date:9/2/2014)... Sept. 2, 2014  Numotion is pleased to announce the ... of Directors. Mark is a 30-year retired ... positions across the organization and was a GE Company Officer ... Mark spent many years running business units within GE Healthcare, ... Healthcare Americas. "We are delighted to welcome ...
(Date:9/2/2014)... , Sept. 2, 2014  On July 31, ... to Congress that it is moving forward to regulate ... the minutes until laboratories throughout the U.S. will need ... Although some medical laboratories may subscribe to the ... FDA to put guidelines in place, it,s widely acknowledged ...
Breaking Medicine Technology:Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 2FDA Tells Congress It Intends to Regulate LDTs! Web Conference to Provide Straight Talk on Essential Steps Clinical Laboratories and Pathology Groups Will Need to Take to Comply 3
... Solutions Development Company (MSDC), a drug discovery and ... metabolic diseases, announced today that it has launched ... second drug candidate for the treatment of type ... placebo-controlled clinical trial will involve approximately 125 patients ...
... SAN and NYSE: SNY ) announced today ... Rights (CVRs) offered to Genzyme shareholders as part of ... by the U.S. Securities and Exchange Commission. ... Genzyme, sanofi-aventis has commenced an exchange offer to acquire ...
Cached Medicine Technology:Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 2Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective 3
(Date:9/2/2014)... Evolve Medical Clinics, the first ... urgent care arena, is having its Grand Opening ... health fair the clinic is sponsoring. Evolve offers ... patients in achieving high quality, convenient medical care. ... is a groundbreaking change in healthcare. The membership ...
(Date:9/2/2014)... September 02, 2014 Last year, SIGVARIS ... with the launch of a luxurious line of graduated compression ... the SEA ISLAND COTTON Socks are joining the SIGVARIS MEDICAL ... more people the comfort of natural cotton fibers. , ... are surprised to find socks as soft as the finest ...
(Date:9/2/2014)... Ticket Down is a reputable source ... September will be an exciting week for soccer fans in ... Ecuador and Bolivia will battle on U.S. soil in friendly ... September 5th - September 9th: , Brazil vs. Ecuador ... Mexico vs. Chile Tickets at Levi's Stadium on ...
(Date:9/2/2014)... 02, 2014 The exclusive ClinicCRM patient ... designed to help doctors manage foreign patient flow, enable ... conversion rates and clink revenue. Since its launch in ... in sales revenue and a 70 percent increase in ... their own healthcare practices. , With its ease of ...
(Date:9/2/2014)... but your outpatient doctor does not know? Or ... care, but your doctor does not have the ... or incomplete communication from hospitals to outpatient primary ... and lead to hospital readmissions. , However, ... improve hospitals, communication during patient care transitions. Researchers ...
Breaking Medicine News(10 mins):Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 2Health News:Evolve Medical Clinics Announces Grand Opening of Annapolis, Maryland Location 3Health News:SIGVARIS’ Luxury Line of Compression Socks, SEA ISLAND COTTON, Now Available in Stronger Compression Level 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 2Health News:Ticket Down Substantially Slashes Ticket Prices on Brazil vs. Ecuador Tickets, Brazil vs. Colombia Tickets, Mexico vs. Chile Tickets and Mexico vs. Bolivia Tickets 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Can data motivate hospital leaders to improve care transitions? 2
... developed countries seem to be becoming ever more hectic. With ... reveals that Australian children in the 10-15 year age ... every nigth when compared with just one generation ago. ... television watching are to blame, with adolescents no longer adhering ...
... alcohol will be introduced in England to ward-off people from ... your limits and drink responsibly will be out by the ... ministers and industry. ,The agreement was first planned ... proper format has been adopted. ,Ministers have insisted ...
... extracted from the blood of bird flu survivors have helped ... virus. ,Scientists have long suspected that culling immune-system ... hard-to-treat H5N1 flu strain. ,If the research pans ... immune system's search-and-destroy force, as an additional way to treat ...
... by an American researcher has revealed that bricks made from ... might be safer than predicted. ,Rather than leach ... bricks do the reverse, pulling minute amounts of the toxic ... Henry Liu, a longtime National Science Foundation (NSF) awardee and ...
... tobacco industry for spreading untruths about smoking in public places ... bans around the world. ,The WHO said ... about the health risks and dangers of second-hand tobacco smoke ... ,"We all know that smoking kills," Shigeru Omi, director of ...
... inflammation are more likely to later develop Alzheimer's disease ... to a study published in the May 29, 2007, ... Academy of Neurology. ,The study, which is ... healthy people with an average age of 79. Blood ...
Cached Medicine News:Health News:Australian Children Sleep Less, Perhaps Not Well Monitored 2Health News:UK Introduce New Health Warnings Against Alcohol 2Health News:Blood from Bird Flu Survivors Provides Breakthrough in Treatment of H5N1 2Health News:Fly Ash Bricks are Absolutely Safer Than Actually Predicted 2Health News:WHO Condemns Tobacco Industry for Misleading Public 2
The Vitatron Pirouet S+ lead series are endocardial leads with extendable/retractable helical screw designed for reliable fixation and optimal pacing characteristics....
Used with permanent pacing leads....
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
... the Tupos LV/A+, the single-lead principle has been ... time. The complete system, which consists of the ... minimizes the scope of surgery and the risk ... atrium and the ventricle via a single lead. ...
Medicine Products: